冠昊生物收盘上涨2.57%，滚动市盈率163.32倍，总市值45.55亿元

Group 1 - The core business of the company focuses on developing new products and technologies with independent intellectual property rights, aiming to enhance product quality and optimize product structure as key drivers for growth [2] - The company reported a revenue of 94.79 million yuan for Q1 2025, representing a year-on-year increase of 3.67%, and a net profit of 14.87 million yuan, also up by 3.30%, with a gross profit margin of 77.05% [2] - As of July 18, 2025, the number of shareholders decreased to 30,599, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - The company's current rolling PE ratio is 163.32, which is significantly higher than the industry average of 54.55 and the industry median of 37.54, ranking it 111th in the industry [1][3] - The company is recognized as a "National Intellectual Property Advantage Enterprise" and has several subsidiaries that are classified as high-tech enterprises, contributing to its brand influence and market share [2] - The company operates in three main business segments: biomaterials, pharmaceuticals, and cell therapy, which are expected to develop synergistically [2]